BURLINGTON, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q3 2023 results, announced a $0.14/share quarterly dividend and provided guidance.
Q3 2023 Financial Results
Bovine patches (+22%), valvulotomes (+27%), bovine grafts (+15%) and carotid shunts (+24%) drove Q3 sales. APAC sales increased 30%, EMEA 24% and the Americas 20%.
The gross margin increased to 65.0% in Q3 (vs. 64.2% in Q3 2022) driven largely by price increases.
Operating income of $9.2mm was up 49% vs. Q3 2022. Operating expenses grew 14% year-over-year due to sales rep growth (118 to 136) and higher commissions, as well as CE-related regulatory costs.
George LeMaitre, Chairman and CEO, said “21% sales growth in Q3 and 49% op. income growth resulted from price increases, restrained op. expenses and a return-to-hospital by patients and staff. Our profitability and $97.0mm cash-on-hand provide safety and strategic optionality.”
Business Outlook
| Q4 2023 Guidance | Full Year 2023 Guidance | |
| Sales | $48.0mm - $50.0mm (Mid: $49.0mm, +20%, +16% Org.) | $192.6mm - $194.6mm (Mid: $193.6mm, +20%, +17% Org.) |
| Gross Margin | 65.0% | 64.9% |
| Op. Inc. | $9.4mm - $10.7mm (Mid: $10.0mm, +44%) | $35.9mm - $37.2mm (Mid $36.5mm, +36%) |
| Op. Inc. Ex-Special* | - | $36.4mm - $37.7mm (Mid $37.0mm, +24%) |
| EPS | $0.34 - $0.38 (Mid: $0.36, +43%) | $1.30 - $1.35 (Mid: $1.33, +42%) |
| EPS Ex-Special* | - | $1.32 - $1.36 (Mid: $1.34, +26%) |
*Special charges are related to the St. Etienne factory closure.
Quarterly Dividend
On October 24, 2023, the Company's Board of Directors approved a quarterly dividend of $0.14/share of common stock. The dividend will be paid on November 30, 2023 to shareholders of record on November 16, 2023.
Share Repurchase Program
On February 21, 2023, the Company's Board of Directors authorized the repurchase of up to $25.0mm of the Company’s common stock. The repurchase program may be suspended or discontinued at any time and will conclude on February 21, 2024, unless extended by the Board.
Conference Call Reminder
Management will conduct a conference call at 5:00pm ET today. The conference call will be broadcast live over the Internet. Individuals interested in listening to the webcast can log on to the Company's website at www.lemaitre.com/investor. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at www.lemaitre.com/investor. For individuals unable to join the live conference call, a replay will be available on the Company's website.
A reconciliation of GAAP to non-GAAP results is included in the tables attached to this release.
About LeMaitre
LeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon.
LeMaitre is a registered trademark of LeMaitre Vascular, Inc. This press release may include other trademarks and trade names of the Company.
For more information about the Company, please visit www.lemaitre.com.
Use of Non-GAAP Financial Measures
LeMaitre management believes that in order to better understand the Company's short- and long-term financial trends, investors may wish to consider certain non-GAAP financial measures as a supplement to financial performance measures prepared in accordance with GAAP. Non-GAAP financial measures are not based on a comprehensive set of accounting rules or principles and do not have standardized meanings. These non-GAAP measures result from facts and circumstances that may vary in frequency and/or impact on continuing operations. Non-GAAP measures should be considered in addition to, and not as a substitute for, financial performance measures in accordance with GAAP. In addition to the description provided below, reconciliation of GAAP to non-GAAP results is provided in the financial statement tables included in this press release.
In this press release, the Company has reported non-GAAP sales growth percentages after adjusting for the impact of foreign currency exchange, business development transactions, and/or other events, including EBITDA. This press release also provides guidance for operating income and EPS excluding the special charge relating to the closure of our St. Etienne factory and revenue related the Aziyo distribution agreement. The Company refers to the calculation of non-GAAP sales growth percentages as "organic." The Company analyzes non-GAAP sales on a constant currency basis, net of acquisitions and other non-recurring events, and the aforementioned non-GAAP profitability measures to better measure the comparability of results between periods. Because changes in foreign currency exchange rates have a non-operating impact on net sales, and acquisitions, divestitures, product discontinuations, factory closures, and other strategic transactions are episodic in nature and are highly variable to the reported sales results, the Company believes that evaluating growth in sales on a constant currency basis net of such transactions provides an additional and meaningful assessment of sales to management. The Company believes that the presentation of guidance described above for operating income and EPS provides an alternative and meaningful view of the Company’s profitability.
Forward-Looking Statements
The Company's current financial results, as discussed in this release, are preliminary and unaudited, and subject to adjustment. This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding the Company's business that are not historical facts may be "forward-looking statements" that involve risks and uncertainties. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties that could cause actual results to differ from the results expected, including, but not limited to, the status of our global regulatory approvals and compliance with regulatory requirements to market and sell our products both in the U.S. and outside of the U.S.; the risk of significant fluctuations in our quarterly and annual results due to numerous factors; the risk that assumptions about the market for the Company’s products and the productivity of the Company’s direct sales force and distributors may not be correct; the risk that we may not be able to maintain our recent levels of profitability; the risk that the Company may not realize the anticipated benefits of its strategic activities; risks related to the integration of acquisition targets; the acceleration or deceleration of product growth rates; risks related to product demand and market acceptance of the Company’s products and pricing; the risk that a recall of our products could result in significant costs or negative publicity; the risk that the Company is not successful in transitioning to a direct-selling model in new territories and other risks and uncertainties included under the heading "Risk Factors" in our most recent Annual Report on Form 10-K, as updated by our subsequent filings with the SEC, which are all available on the Company's investor relations website at http://www.lemaitre.com and on the SEC's website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.
| LEMAITRE VASCULAR, INC. (NASDAQ: LMAT) | ||||||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||||||
| (amounts in thousands) | ||||||||||
| September 30, 2023 | December 31, 2022 | |||||||||
| (unaudited) | ||||||||||
| Assets | ||||||||||
| Current assets: | ||||||||||
| Cash and cash equivalents | $ | 18,051 | $ | 19,134 | ||||||
| Short-term marketable securities | 78,967 | 63,557 | ||||||||
| Accounts receivable, net | 23,882 | 22,040 | ||||||||
| Inventory and other deferred costs | 56,187 | 50,271 | ||||||||
| Prepaid expenses and other current assets | 5,097 | 6,731 | ||||||||
| Total current assets | 182,184 | 161,733 | ||||||||
| Property and equipment, net | 21,357 | 17,901 | ||||||||
| Right-of-use leased assets | 15,850 | 15,634 | ||||||||
| Goodwill | 65,945 | 65,945 | ||||||||
| Other intangibles, net | 43,199 | 46,527 | ||||||||
| Deferred tax assets | 2,325 | 1,745 | ||||||||
| Other assets | 3,152 | 991 | ||||||||
| Total assets | $ | 334,012 | $ | 310,476 | ||||||
| Liabilities and stockholders' equity | ||||||||||
| Current liabilities: | ||||||||||
| Accounts payable | $ | 4,371 | $ | 2,903 | ||||||
| Accrued expenses | 21,788 | 19,967 | ||||||||
| Acquisition-related obligations | 121 | 573 | ||||||||
| Lease liabilities - short-term | 2,749 | 1,886 | ||||||||
| Total current liabilities | 29,029 | 25,329 | ||||||||
| Lease liabilities - long-term | 14,132 | 14,710 | ||||||||
| Deferred tax liabilities | 69 | 69 | ||||||||
| Other long-term liabilities | 2,145 | 2,167 | ||||||||
| Total liabilities | 45,375 | 42,275 | ||||||||
| Stockholders' equity | ||||||||||
| Common stock | 239 | 237 | ||||||||
| Additional paid-in capital | 198,254 | 189,268 | ||||||||
| Retained earnings | 110,081 | 97,773 | ||||||||
| Accumulated other comprehensive loss | (6,705 | ) | (6,031 | ) | ||||||
| Treasury stock | (13,232 | ) | (13,046 | ) | ||||||
| Total stockholders' equity | 288,637 | 268,201 | ||||||||
| Total liabilities and stockholders' equity | $ | 334,012 | $ | 310,476 | ||||||
| LEMAITRE VASCULAR, INC. (NASDAQ: LMAT) | ||||||||||||||||
| CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS | ||||||||||||||||
| (amounts in thousands, except per share amounts) | ||||||||||||||||
| (unaudited) | ||||||||||||||||
| For the three months ended | For the nine months ended | |||||||||||||||
| September 30, 2023 | September 30, 2022 | September 30, 2023 | September 30, 2022 | |||||||||||||
| Net sales | $ | 47,411 | $ | 39,028 | $ | 144,601 | $ | 120,697 | ||||||||
| Cost of sales | 16,596 | 13,958 | 50,817 | 41,855 | ||||||||||||
| Gross profit | 30,815 | 25,070 | 93,784 | 78,842 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Sales and marketing | 9,673 | 8,229 | 30,786 | 24,321 | ||||||||||||
| General and administrative | 7,738 | 7,229 | 23,392 | 21,812 | ||||||||||||
| Research and development | 4,224 | 3,462 | 12,615 | 9,740 | ||||||||||||
| Restructuring | - | - | 485 | 3,107 | ||||||||||||
| Total operating expenses | 21,635 | 18,920 | 67,278 | 58,980 | ||||||||||||
| Income from operations | 9,180 | 6,150 | 26,506 | 19,862 | ||||||||||||
| Other income (expense): | ||||||||||||||||
| Interest income | 835 | 264 | 2,085 | 539 | ||||||||||||
| Foreign currency gain (loss) | (189 | ) | (266 | ) | (429 | ) | (709 | ) | ||||||||
| Income before income taxes | 9,826 | 6,148 | 28,162 | 19,692 | ||||||||||||
| Provision for income taxes | 2,324 | 692 | 6,522 | 4,683 | ||||||||||||
| Net income | $ | 7,502 | $ | 5,456 | $ | 21,640 | $ | 15,009 | ||||||||
| Earnings per share of common stock | ||||||||||||||||
| Basic | $ | 0.34 | $ | 0.25 | $ | 0.97 | $ | 0.68 | ||||||||
| Diluted | $ | 0.33 | $ | 0.25 | $ | 0.97 | $ | 0.68 | ||||||||
| Weighted - average shares outstanding: | ||||||||||||||||
| Basic | 22,263 | 21,984 | 22,196 | 21,959 | ||||||||||||
| Diluted | 22,481 | 22,217 | 22,411 | 22,149 | ||||||||||||
| Cash dividends declared per common share | $ | 0.140 | $ | 0.125 | $ | 0.420 | $ | 0.375 | ||||||||
| LEMAITRE VASCULAR, INC. (NASDAQ: LMAT) | ||||||||||||||||||||||||
| SELECTED NET SALES INFORMATION | ||||||||||||||||||||||||
| (amounts in thousands) | ||||||||||||||||||||||||
| (unaudited) | ||||||||||||||||||||||||
| For the three months ended | For the nine months ended | |||||||||||||||||||||||
| September 30, 2023 | September 30, 2022 | September 30, 2023 | September 30, 2022 | |||||||||||||||||||||
| $ | % | $ | % | $ | % | $ | % | |||||||||||||||||
| Net Sales by Geography | ||||||||||||||||||||||||
| Americas | $ | 31,863 | 67 | % | $ | 26,627 | 68 | % | $ | 97,496 | 67 | % | $ | 82,024 | 68 | % | ||||||||
| Europe, Middle East and Africa | 12,322 | 26 | % | 9,922 | 25 | % | 38,179 | 26 | % | 31,165 | 26 | % | ||||||||||||
| Asia Pacific | 3,226 | 7 | % | 2,479 | 7 | % | 8,926 | 7 | % | 7,508 | 6 | % | ||||||||||||
| Total Net Sales | $ | 47,411 | 100 | % | $ | 39,028 | 100 | % | $ | 144,601 | 100 | % | $ | 120,697 | 100 | % | ||||||||
| LEMAITRE VASCULAR, INC (NASDAQ: LMAT) | |||||||||||||||||||
| NON-GAAP FINANCIAL MEASURES | |||||||||||||||||||
| (amounts in thousands) | |||||||||||||||||||
| (unaudited) | |||||||||||||||||||
| For the three months ended | For the nine months ended | ||||||||||||||||||
| September 30, 2023 | September 30, 2022 | September 30, 2023 | September 30, 2022 | ||||||||||||||||
| Reconciliation between GAAP and Non-GAAP EBITDA | |||||||||||||||||||
| Net income as reported | $ | 7,502 | $ | 5,456 | $ | 21,640 | $ | 15,009 | |||||||||||
| Interest (income) expense, net | (835 | ) | (264 | ) | (2,085 | ) | (539 | ) | |||||||||||
| Amortization and depreciation expense | 2,395 | 2,328 | 7,072 | 7,145 | |||||||||||||||
| Provision for income taxes | 2,324 | 692 | 6,522 | 4,683 | |||||||||||||||
| EBITDA | $ | 11,386 | $ | 8,212 | $ | 33,149 | $ | 26,298 | |||||||||||
| EBITDA percentage increase | 39 | % | 26 | % | |||||||||||||||
| LEMAITRE VASCULAR, INC. (NASDAQ: LMAT) | |||||||||||||
| NON-GAAP FINANCIAL MEASURES | |||||||||||||
| (amounts in thousands) | |||||||||||||
| (unaudited) | |||||||||||||
| Reconciliation between GAAP and Non-GAAP sales growth: | |||||||||||||
| For the three months ended September 30, 2023 | |||||||||||||
| Net sales as reported | $ | 47,411 | |||||||||||
| Net distribution sales | (1,341 | ) | |||||||||||
| Impact of currency exchange rate fluctuations | (728 | ) | |||||||||||
| Adjusted net sales | $ | 45,342 | |||||||||||
| For the three months ended September 30, 2022 | |||||||||||||
| Net sales as reported | $ | 39,028 | |||||||||||
| Adjusted net sales | $ | 39,028 | |||||||||||
| Adjusted net sales increase for the three months ended September 30, 2023 | $ | 6,314 | 16 | % | |||||||||
| Reconciliation between GAAP and Non-GAAP projected sales growth: | |||||||||||||
| For the three months ending December 31, 2023 | |||||||||||||
| Net sales per guidance (midpoint) | $ | 49,000 | |||||||||||
| Net distribution sales | (1,341 | ) | |||||||||||
| Impact of currency exchange rate fluctuations | (333 | ) | |||||||||||
| Adjusted projected net sales | $ | 47,326 | |||||||||||
| For the three months ended December 31, 2022 | |||||||||||||
| Net sales as reported | $ | 40,954 | |||||||||||
| Adjusted net sales | $ | 40,954 | |||||||||||
| Adjusted projected net sales increase for the three months ending December 31, 2023 | $ | 6,372 | 16 | % | |||||||||
| Reconciliation between GAAP and Non-GAAP projected sales growth: | |||||||||||||
| For the year ending December 31, 2023 | |||||||||||||
| Net sales per guidance (midpoint) | $ | 193,601 | |||||||||||
| Net distribution sales | (3,915 | ) | |||||||||||
| Impact of currency exchange rate fluctuations | 3 | ||||||||||||
| Adjusted projected net sales | $ | 189,689 | |||||||||||
| For the year ended December 31, 2022 | |||||||||||||
| Net sales as reported | $ | 161,651 | |||||||||||
| Adjusted net sales | $ | 161,651 | |||||||||||
| Adjusted projected net sales increase for the year ending December 31, 2023 | $ | 28,038 | 17 | % | |||||||||
| Reconciliation between GAAP and Non-GAAP projected operating income: | |||||||||||||
| For the year ending December 31, 2023 | |||||||||||||
| Operating income per guidance (midpoint) | $ | 36,506 | |||||||||||
| Impact of special charge | 485 | ||||||||||||
| Adjusted projected operating income | $ | 36,991 | |||||||||||
| For the year ended December 31, 2022 | |||||||||||||
| Operating income as reported | $ | 26,829 | |||||||||||
| Impact of special charge | 3,107 | ||||||||||||
| Adjusted operating income | $ | 29,936 | |||||||||||
| Adjusted projected operating income increase for the year ending December 31, 2023 | $ | 7,055 | 24 | % | |||||||||
| Reconciliation between GAAP and Non-GAAP projected EPS: | |||||||||||||
| For the year ending December 31, 2023 | |||||||||||||
| EPS per guidance (midpoint) | $ | 1.33 | |||||||||||
| Impact of special charge, including tax | 0.01 | ||||||||||||
| Adjusted EPS | $ | 1.34 | |||||||||||
| For the year ended December 31, 2022 | |||||||||||||
| EPS as reported | $ | 0.93 | |||||||||||
| Impact of special charge, including tax | 0.13 | ||||||||||||
| Adjusted EPS | $ | 1.06 | |||||||||||
| Adjusted projected EPS increase for the year ending December 31, 2023 | $ | 0.28 | 26 | % | |||||||||
| Last Trade: | US$92.02 |
| Daily Change: | 0.64 0.70 |
| Daily Volume: | 18,380 |
| Market Cap: | US$2.070B |
December 16, 2024 October 31, 2024 August 01, 2024 May 02, 2024 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
